Editas (NASDAQ:EDIT) completed their IPO this week in a difficult market and is now the first "pure play" on CRISPR. In the biotechnology field CRISPR is viewed as the Next Big Thing. Journals like the MIT Technology Review have called it "the biggest biotechnology discovery of the century." For decades money has been poured into bringing down the cost of mapping the genome. Most agree that the mapping problem is behind us as costs are reasonable and still declining. This provides the foundation to take the next step - modifying those genomes.
At a very high level CRISPR . . .